China Tracker - Details for Jiangbo Pharmaceuticals (JGBO)

 Jiangbo Pharmaceuticals
 Basic Facts and History
Data Source: Annual Report for the period ended 2010-06-30
Reporting Type: U.S. Company (10-K Filings) 
Incorporation: Florida 
Corporate Headquarters: China (Shandong) 
Going Public: Reverse Merger on 2007-10-01 
Previous Entity: Genesis Pharmaceuticals Enterprises, Inc. 
Uplisting to Senior Exchange: on 2010-06-08 at $8.20 (-100.00% since Uplisting)
Main Operating Subsidiary: Laiyang Jiangbo Pharmaceutical Co., founded 2003 
Investor Relations: Investor Relations Website 
Internal Controls: not effective 
Internal Controls Audit: not performed 
Auditor Opinion:

The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. (Frazer Frost)

This company is overdue with their latest quarterly or annual report! The Trading China Rating is suspended until the company is back in compliance with SEC filing rules.

This company has been publicly accused with fraud! You may want to look further into possible issues before making an investment decision. Trading China makes no judgment on the validity of fraud accusations, however the Trading China Rating is suspended until those issues are fully resolved.

 
 Ownership
Main Shareholder: Cao Wubo (Chairman) 
Ownership: 38.76% 
 
 Auditor Trail (since January 1, 2009)
2011-04-19Marcum Bernstein & PinchukAppointment (Merger)
2011-04-19Bernstein & PinchukResignation (Merger)
2011-03-30Bernstein & PinchukAppointment
2011-03-30Frazer FrostContract Expired
2010-01-01Frazer FrostAppointment (Merger)
2010-01-01Moore Stephens Wurth Frazer and TorbetResignation (Merger)
2008-02-25Moore Stephens Wurth Frazer and TorbetAppointment
2008-02-25Sherb & Co.Dismissal
 
 Senior Management Trail (since January 1, 2009)
2011-03-15Elsa SungCFOResignation
2007-10-01Elsa SungCFOAppointment
 
 Fiscal Year
Fiscal Year ends: June 30 
First Quarter 10-Q: due by 2017-11-15 
Second Quarter 10-Q: due by 2018-02-15 
Third Quarter 10-Q: due by 2017-05-15 
Annual Report 10-K: due by 2017-09-30 
JGBO
Healthcare & Drugs
SCORE
-1
UNDER REVIEW
READ: Score Cards Explained
SAFETY/RISK SCORE
EXTREME RISK
DETAILS: Safety/Risk Model for JGBO
Current Price:  n/a
F10k Day (2007-10-02): -100.00%$12.40
2009 Close: -100.00%$11.00
2010 Close: -100.00%$5.72
2011 Close: -100.00%$0.13
High (2012-06-26): -100.00%$0.17
Low (2012-10-18): -100.00%$0.06
Exchange: N/A
Market Capitalization: n/a
Total Shares: 15.66 mill
Float: n/a
Avg Volume: n/a
Short Interest: 138.80 k
Short Ratio: 1.44%n/a
Last Quarter: 2011-03-31
Revenue (MRQ): 18.11 mill
Net Income (MRQ): 2.30 mill
Op. Cash Flow (MRQ): 9.90 mill
all financial data provided without warranty